iMDx kidney transplant test featured in Lancet study, gets Medicare nod
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St futures muted as oil tops $100 for first time since July
- Oil nears $100 as fresh Middle East strikes raise supply risks
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication
July 23, 2026 8:00 AM EDTStudy published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejectionSerial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisionsNew study signals GraftAssure assays market expansion opportunity as drugs to treat organ rejection work their way through clinical trialsiMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing
NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight... More
